Cargando…

Primary breast diffuse large B-cell lymphoma in the era of rituximab

BACKGROUND AND OBJECTIVE: The aim of this study was to summarize the clinical characteristics and evaluate the management approaches of primary breast diffuse large B-cell lymphoma (DLBCL) in the era of rituximab. PATIENTS AND METHODS: A total of 24 female patients with newly diagnosed primary breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Na, Cao, Caineng, Zhu, Yuan, Liu, Peng, Liu, Luying, Lu, Ke, Luo, Jialin, Zhou, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065257/ https://www.ncbi.nlm.nih.gov/pubmed/27785056 http://dx.doi.org/10.2147/OTT.S108839

Ejemplares similares

Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma
por: Luo, Jialin, et al.
Publicado: (2016)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B‐cell lymphoma in the rituximab era
por: Ishikawa, Eri, et al.
Publicado: (2018)

Clinical outcome of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era
por: Sato, Ai, et al.
Publicado: (2014)

Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kang, Jihoon, et al.
Publicado: (2017)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era
por: Kawajiri, A, et al.
Publicado: (2016)

Primary breast diffuse large B cell lymphoma
por: Guo, Mengni, et al.
Publicado: (2022)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab
por: McLaughlin, Christopher, et al.
Publicado: (2022)

P1200: RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY
por: Lee, H. J., et al.
Publicado: (2022)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis
por: Zhou, Xuan, et al.
Publicado: (2017)

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
por: Mondello, Patrizia, et al.
Publicado: (2014)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma
por: Chen, Guang-Liang, et al.
Publicado: (2022)

Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
por: Fan, Liping, et al.
Publicado: (2021)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance
por: Boyle, Stephen, et al.
Publicado: (2021)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
por: Kim, Kyung Min, et al.
Publicado: (2009)

Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
por: Hu, Yunfei, et al.
Publicado: (2014)

Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma
por: Liu, Xiaohong, et al.
Publicado: (2022)

A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era
por: Lim, Ryan Mao Heng, et al.
Publicado: (2020)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
por: Ko Ko, Nway Le, et al.
Publicado: (2020)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6r9544e3a3odrooh9jaosk11q0